Livanova Plc Stock Price, News & Analysis

LivaNova PLC (NASDAQ: LIVN) will hold a conference call on November 2, 2022, at 12 p.m. London time (8 a.m. EDT) to discuss its third-quarter 2022 results, releasing the details prior to the call. Interested participants can access a live audiocast at www.livanova.com/events. Call-in options are also available for both U.S. and international listeners. A replay will be offered for 90 days post-call. LivaNova is headquartered in London, employing approximately 3,000 people globally, focusing on innovative medical technologies for patients.

LivaNova PLC (NASDAQ: LIVN) announced the appointment of Brooke Story to its Board of Directors, effective September 15, 2022. Story brings over 20 years of experience in medical technology, currently serving as Worldwide President, Integrated Diagnostic Solutions at BD (NYSE: BDX). She previously held leadership roles at Medtronic, enhancing her expertise in the industry. The Board's Chair, William Kozy, emphasized Story's capability in fostering talent and delivering economic value, which is expected to support LivaNova's growth and innovation strategies.

LivaNova PLC (Nasdaq: LIVN) reported a 3.9% decline in revenue, totaling $254.2 million for Q2 2022, though constant-currency revenue increased by 0.5%. Excluding the divested Heart Valves business, revenue grew by 1.8% on a reported basis and 6.5% in constant-currency terms. The diluted earnings per share was $0.30, with adjusted diluted EPS at $0.53. The company anticipates a 4-6% revenue growth for full-year 2022 before currency impacts, while foreign exchange is expected to create a 4-5% headwind. Full-year adjusted EPS is projected between $2.25 and $2.45.

LivaNova PLC (NASDAQ: LIVN) will hold a conference call on August 3, 2022, at 1 p.m. London time (8 a.m. EDT) to discuss its second-quarter 2022 results. The results will be released prior to the call. Interested parties can access a live audiocast on the LivaNova website and also participate via telephone using the specified dialing numbers. A replay will be available for 90 days post-call. LivaNova is a global medical technology company committed to innovative solutions for patients worldwide.

LivaNova PLC (NASDAQ: LIVN) announced that Peter Wilver has joined its Board of Directors, effective immediately, following the company's 2022 AGM on June 13. Wilver brings over 30 years of experience, having previously held significant roles at Thermo Fisher Scientific, Honeywell, and General Electric. His expertise in strategic planning and financial operations is expected to enhance the Board's oversight. Alongside Wilver, eight current directors were re-elected, solidifying leadership continuity within the organization.

LivaNova PLC (Nasdaq: LIVN) announced that CEO Damien McDonald will present at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15 at 10 a.m. Pacific Time in Rancho Palos Verdes, California. The presentation will be available via webcast for registered participants. Interested individuals should log on 10 minutes early for setup. A replay will be accessible on www.livanova.com within 24 hours for 30 days post-event.

LivaNova is dedicated to innovative medical technologies, employing about 3,000 staff globally.

LivaNova PLC (Nasdaq: LIVN) reported Q1 2022 results with worldwide sales of $240.2 million, down 3.0% year-over-year. Excluding divested Heart Valves, sales increased 6.2%. U.S. GAAP diluted earnings per share were $0.06, while adjusted EPS reached $0.48. Key advancements included the implantation of 250 unipolar depression patients in ongoing trials and the acquisition of ALung Technologies. LivaNova projects 2022 sales growth between 3-5% and adjusted EPS of $2.50 to $2.80. Despite macroeconomic challenges, growth was noted in Cardiopulmonary and Neuromodulation segments.

LivaNova PLC (NASDAQ: LIVN) announced the launch of the Essenz Patient Monitor, designed to enhance clinical efficiency during cardiopulmonary bypass procedures. The monitor has received FDA 510(k) clearance and CE Mark, enabling its initial deployment in select U.S. and European hospitals. Developed through collaboration with perfusionists, it offers advanced data display and decision-making support. Future stages will include the complete Essenz Perfusion System, aimed at improving patient outcomes through goal-directed perfusion strategies.

LivaNova, a global medical technology company, will hold a conference call on May 4, 2022, at 1 p.m. London time to discuss its first-quarter 2022 results. The results will be released prior to the call. Interested parties can access the audiocast on the company's website or by telephone. LivaNova, headquartered in London, focuses on innovative medical technologies to improve patient care, with a workforce of about 3,000 and operations in over 100 countries. A replay of the call will be available for 90 days.